EpiCept Corporation to Present at the 2007 BIO International Convention
TARRYTOWN, N.Y., May 04, 2007 /PRNewswire-FirstCall/ — EpiCept Corporation today announced that the Company’s management will be making three presentations at the 2007 BIO International Convention, taking place May 6 through May 9, 2007 at the Boston Convention and Exhibition Center, Boston, MA.
Jack Talley, President and CEO, will participate in a Breakout Session entitled, “Creative Financing Options for Development-Stage Companies,” being held on Monday, May 7, 2007 at 9:15 a.m. EDT, in Room 204 AB.
Mr. Talley will also be presenting a Company overview at the BIO Business Forum on Tuesday May 8, 2007 at 2:00 p.m. EDT, in Room E.
In addition, Ben Tseng, Ph.D., EpiCept’s Chief Scientific Officer, will be giving a poster presentation of EpiCept’s Anti-cancer Screening Apoptosis Platform (ASAP) on Tuesday, May 8, 2007 from 1:00 p.m. - 4:00 p.m. EDT, at the Level 1 North Lobby.
EpiCept’s ASAP technology has been demonstrated to efficiently identify new cancer drug candidates and molecular targets that selectively induce apoptosis in cancer cells through the use of the Company’s proprietary live cell high-throughput caspase-3 screening technology and chemical genetics. Four lead compounds have been identified to date with two currently in clinical trials; Azixa(TM)* in Phase II (licensed to Myriad Genetics) and EPC2407 in Phase I. Two other lead candidates have been identified along with their molecular targets which are novel pathways for the activation of apoptosis. The presentation will describe the platform and examples, EPC2407 and EP2167, of lead discovery and target identification.
More information on the BIO International Convention can be found at http://www.bio2007.org.
About EpiCept Corporation
EpiCept is focused on unmet needs in the treatment of pain and cancer. EpiCept has a staged portfolio of pharmaceutical product candidates with several pain therapies in late-stage clinical trials, and a lead oncology compound (for acute myeloid leukemia, or AML) with demonstrated efficacy in a Phase III trial; a marketing authorization application for this compound has been submitted in Europe. EpiCept is based in Tarrytown, N.Y., and its research and development team in San Diego is pursuing a drug discovery program focused on novel approaches to apoptosis.
Forward-Looking Statements
This news release and any oral statements made with respect to the information contained in this news release, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements which express plans, anticipation, intent, contingency, goals, targets, future development and are otherwise not statements of historical fact. These statements are based on EpiCept’s current expectations and are subject to risks and uncertainties that could cause actual results or developments to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results or developments to differ materially include: the risk that Myriad’s development of Azixa will not be successful, the risk that Azixa will not receive regulatory approval or achieve significant commercial success, the risk that we will not receive any significant payments under our agreement with Myriad, the risk that the development of our other apoptosis product candidates will not be successful, the risk that our ASAP technology will not yield any successful product candidates, the risk that clinical trials for NP- 1 will not be successful, that NP-1 will not receive regulatory approval or achieve significant commercial success, the risk that Ceplene will not receive regulatory approval or marketing authorization in the EU, the risk that our other product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later stage clinical trials, the risk that EpiCept will not obtain approval to market any of its product candidates, the risks associated with reliance on additional outside financing to meet our capital requirements, the risks associated with dependence upon key personnel, the risks associated with reliance on collaborative partners and others for further clinical trials, development, manufacturing and commercialization of our product candidates; the cost, delays and uncertainties associated with our scientific research, product development, clinical trials and regulatory approval process; our history of operating losses since our inception; competition; litigation; risks associated with our ability to have our common stock readmitted to trading on The Nasdaq Global Market; risks associated with prior material weaknesses in our internal controls; and risks associated with our ability to protect our intellectual property. These factors and other material risks are more fully discussed in EpiCept’s periodic reports, including its reports on Forms 8-K, 10-Q and 10-K and other filings with the U.S. Securities and Exchange Commission. You are urged to carefully review and consider the disclosures found in EpiCept’s filings which are available at www.sec.gov or at www.epicept.com. You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be wrong due to inaccurate assumptions, unknown risks or uncertainties or other risk factors.
*Azixa(TM) is a trademark of Myriad Genetics, Inc.
